Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients (CLAIM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02442206 |
Recruitment Status :
Completed
First Posted : May 13, 2015
Results First Posted : December 3, 2018
Last Update Posted : January 3, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease, COPD | Drug: QVA149 Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 62 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blinded, Single-center, Placebo Controlled, Cross-over Study to Assess the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) on Cardiac Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
Actual Study Start Date : | May 18, 2015 |
Actual Primary Completion Date : | April 20, 2017 |
Actual Study Completion Date : | May 15, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment sequence 1
QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
|
Drug: QVA149
QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Other Name: Ultibro Drug: Placebo Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily |
Experimental: Treatment sequence 2
Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
|
Drug: QVA149
QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Other Name: Ultibro Drug: Placebo Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily |
- Change in Left Ventricular End-diastolic Volume (LVEDV) [ Time Frame: Baseline, week 2 ]Left ventricular enddiastolic volume (LVEDV) is a measurement of the volume of blood in the heart's left ventricular chamber at the end of the chamber's filling with blood and will be determined as measured by MRI.
- Change in Forced Expiratory Volume in One Second (FEV1). [ Time Frame: Baseline, week 2 ]Forced Expiratory Volume in one second (FEV1) will be calculated as the volume of air forcibly exhaled in one second as measured by spirometry.
- Change in Forced Vital Capacity (FVC). [ Time Frame: Baseline, week 2 ]Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be assessed via spirometry.
- Change in Inspiratory Capacity (IC) at Each Time-point [ Time Frame: Baseline, week 2 ]Inspiratory capacity (IC) was defined as the mean of the maximum IC over 3 values measured by bodyplethysmography according to internationally accepted standards.
- Change in Total Lung Capacity (TLC) [ Time Frame: Baseline, week 2 ]Total Lung Capacity (TLC) will be calculated from the mean Functional Residual Capacity (FRC) plus the highest value of the Inspiratory Capacity, both measured by body plethymography according to internationally accepted standards.
- Change in Residual Volume (RVol) [ Time Frame: Baseline, week 2 ]Residual Volume (RVol) will be calculated from the value of Total Lung Capacity (TLC) minus the highest value of the Slow Vital Capacity, both measured by body plethymography according to internationally accepted standards.
- Change in Specific Airway Resistance (sRaw) [ Time Frame: Baseline, week 2 ]Specific Airway Resistance (sRaw) will be documented as effective resistance (sReff) calculated as the median of five acceptable measurements. Values will be measured by body plethymography according to internationally accepted standards.
- Change in Functional Residual Capacity (FRC) [ Time Frame: Baseline, week 2 ]Functional Residual Capacity (FRC) will be calculated as the mean of three reproducible values as measured by body plethymography according to internationally accepted standards.
- Change in Right Ventricular (RV) and Left Ventricular (LV) Ejection Fraction (EF) [ Time Frame: Baseline, week 2 ]Right and left ventricular ejection fraction is the fraction of blood (in percent) pumped out of the heart's left and right ventricular chamber, respectively, with each heart beat and will be determined as measured by MRI.
- Change in Left and Right Ventricular End-systolic Volume [ Time Frame: Baseline, week 2 ]Right ventricular end-systolic volume (RV-ESV) and left ventricular end-systolic volume (LV-ESV) is a measurement of the volume of blood in the heart's right and left ventricular chamber, respectively, at the end of the heart's contraction and will be determined as measured by MRI.
- Change in Right Ventricular Enddiastolic Volume [ Time Frame: Baseline, week 2 ]Right ventricular end-diastolic volume is a measurement of the volume of blood in the heart's right ventricular chamber at the end of the chamber's filling with blood and will be determined as measured by MRI.
- Cardiac Output at Each Time-point, Left and Right Ventricular Cardiac Output (LVCO and RVCO) [ Time Frame: week 2 ]Cardiac output is calculated as the heart rate multiplied by the stroke volume (= difference between ventricular enddiastolic volume and endsystolic volume) that will be determined as measured by MRI.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with airflow limitation indicated by a post-bronchodilator FEV1 <80% of the predicted normal value and a post-bronchodilator FEV1/FVC<0.7
- Current or ex-smokers who have a smoking history of at least 10 pack years.
- Able and willing to give written informed consent
- Hyperinflated patients with RVol>135% predicted
Exclusion Criteria:
- Patients on LABA or LAMA treatment at Visit 1.
- History of one COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization 3 months prior to Visit 2.
- More than one COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization within 6 months prior to Visit 2.
- Patients who have clinically significant cardiovascular abnormalities, which could interfere with the assessment of the study treatment (such as but not limited to cardiac arrhythmias, heart failure with left ventricular ejection fraction <40% as determined by MRI scan, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, history of myocardial infarction 6 months prior to Visit 2)
- Patients with a known history or current atrial fibrillation to be confirmed by ECG.
- Patients with pacemaker, bypass or stent.
- Patients whose QTcF measured at Visit 3 is >450 ms for males and >470 ms for females
Additional study-specific inclusion and exclusion criteria may apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02442206
Germany | |
Novartis Investigative Site | |
Hannover, Germany, 30625 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Documents provided by Novartis ( Novartis Pharmaceuticals ):
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT02442206 |
Other Study ID Numbers: |
CQVA149ADE05 2014-004680-21 ( EudraCT Number ) |
First Posted: | May 13, 2015 Key Record Dates |
Results First Posted: | December 3, 2018 |
Last Update Posted: | January 3, 2019 |
Last Verified: | December 2018 |
QVA149, cardiac function, ventricular enddiastolic volume, hyperinflated COPD patients |
Lung Diseases Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases |